FilingSEC EDGAR8-K
Phio Pharmaceuticals Submits Data to FDA for PH-762 Phase 2b Study
· SEC accepted
StageClinical Preparation
Filing content
Phio Pharmaceuticals completed its Phase 1b trial and submitted data to the FDA to support a planned Phase 2b neoadjuvant study for PH-762.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…